Page 188 - Binder2

The conventional model for biological drug production is
centralized, capital-intensive, and vertically integrated. It
depends on multimillion-dollar stainless steel bioreactors,
tightly controlled fermentation environments, and global
cold-chain distribution networks. This model works—but
only in places with the resources to sustain it.

Plant-based manufacturing flips that model on its head.

Rather than scaling vertically, it scales horizontally.
Rather than concentrating production in a few industrial
hubs, it enables decentralized, site-adapted output.
Rather than isolating the drug from nature, it leverages
biology as both the factory and the formulation.

This is not a manufacturing workaround. It’s a new
operating system for therapeutic production—modular,
adaptive, and deeply aligned with how the immune system
itself works. Here is a break down its key principles:

186